This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Kadmon Corporation, LLC. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: David Eiznhamer: Innovator in Chronic Graft Versus Host Disease Treatment
Introduction
David Eiznhamer is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of chronic graft-versus-host disease (cGVHD). His innovative approach focuses on improving patient outcomes through tailored administration methods.
Latest Patents
Eiznhamer holds a patent for "Methods of administering Belumosudil for treatment of chronic graft versus host disease." This patent outlines methods for administering belumosudil mesylate salt to patients suffering from cGVHD. The methods include identifying adverse reactions, such as infections, and adjusting the administration accordingly. For instance, the administration may be ceased if the infection reaches a Grade 3 or Grade 4 level.
Career Highlights
David Eiznhamer is currently associated with Kadmon Corporation, LLC, where he continues to work on innovative treatments. His dedication to advancing medical science is evident in his research and development efforts.
Collaborations
Eiznhamer collaborates with various professionals in the field, including his coworker, Heidi Krenz. Their combined expertise contributes to the ongoing development of effective treatment methods for patients.
Conclusion
David Eiznhamer's work in the treatment of chronic graft-versus-host disease exemplifies the impact of innovation in medicine. His patent and ongoing research efforts highlight the importance of tailored treatment approaches for improving patient care.